Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial

Documenti analoghi

• Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial
  di: Xu, Fengrui, et al.
  Pubblicazione: (2019)
• A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients
  di: Wang, Tao, et al.
  Pubblicazione: (2019)
• Erratum to prophylaxis of breast cancer chemotherapy for bone marrow toxicity: more individualized and safer
  di: Xu, Fengrui, et al.
  Pubblicazione: (2020)
• A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available
  di: Tirelli, Umberto, et al.
  Pubblicazione: (2020)
• Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study
  di: Ma, Jun, et al.
  Pubblicazione: (2021)